Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …

Breast cancer cells disseminate through TIE2/MENACalc/MENAINV-dependent cancer cell
intravasation sites, called tumor microenvironment of metastasis (TMEM), which are …

Recent pre-clinical and clinical research has provided evidence that cancer progression is
driven not only by a tumour's underlying genetic alterations and paracrine interactions within …

Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

As angiogenesis is essential for tumor growth and metastasis, controlling tumor-associated
angiogenesis is a promising tactic in limiting cancer progression. The tumor …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Metastasis is a multistage process that requires cancer cells to escape from the primary
tumour, survive in the circulation, seed at distant sites and grow. Each of these processes …

Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling
pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in …

The dependency of the growth of tumors on blood vessels, once considered a doubtful
proposition, has become a major avenue of research and drug development. This review …